New kanamycin compound, kanamycin-producing streptomyces species bacterium, and method of producing kanamycin
AssigneeEwha University-Industry Collaboration Foundation
InventorsYeo Joon Yoon, Sung Ryeol Park, Je Won Park, Jae Kyung Sohng
Life of this patent
Estimating the term…
Abstract
Vectors expressing kanA-kanB-kanK and other kanamycin production-related genes, Streptomyces<i/> species recombinant bacteria transformed with the vectors, a method of producing kanamycin antibiotics by the bacteria, and a new kanamycin compound produced by the bacterium are provided. With the use of the recombinant bacteria of the present invention, the direct fermentative biosynthesis of amikacin and tobramycin as semi-synthetic kanamycins is possible, and the yield of kanamycin B as a precursor of the semi-synthetic kanamycin is improved.
Claims23
A vector comprising at least one gene set selected from the group consisting of:
- (1) kanA, kanB, and kanK;
- (2) kanA, kanB, kanK, and kanF;
- (3) kanA, kanB, kanK, kanF, and kacA;
- (4) kanA, kanB, kanK, kanF, kacA, kanC, and kanD;
- (5) kanA, kanB, kanK, kanF, kacA, kanI, and kacL;
- (6) kanA, kanB, kanK, kanF, kacA, and kanE;
- (7) kanA, kanB, kanK, kanF, kacA, kanE, kanC, and kanD;
- (8) kanA, kanB, kanK, kanF, kacA, kanE, kanI, and kacL;
- (9) kanA, kanB, kanK, kanF, kacA, kanE, kanC, kanD, kanI, and kacL;
- (10) kanA, kanB, kanK, kanF, kacA, kanE, kanC, kanD, btrG, btrH, btrI, btrJ, btrK, btrO, and btrV;
- (11) kanA, kanB, kanK, kanF, kacA, kanE, kanC, kanD, kanI, kacL, btrG, btrH, btrI, btrJ, btrK, btrO, and btrV;
- (12) kanA, kanB, kanK, and nemD;
- (13) kanA, kanB, kanK, nemD, kacA, kanE, kanC, and kanD;
- (14) kanA, kanB, kanK, nemD, kacA, kanE, kanC, kanD, kanI, and kacL;
- (15) kanA, kanB, kanK, nemD, kacA, kanE, kanC, kanD, kanI, kacL, aprD3, and aprD4;
- (16) kanA, kanB, kanK, nemD, kacA, tobM2, kanC, kanD, kanI, kacL, aprD3, and aprD4;
- (17) kanA, kanB, kanK, and tobM1;
- (18) kanA, kanB, kanK, tobM1, kacA, kanE, kanC, and kanD;
- (19) kanA, kanB, kanK, and gtmG;
- and
- (20) kanA, kanB, kanK, gtmG, kacA, kanE, kanC, and kanD.
A Streptomyces species bacterium expressing at least one gene set selected from the group consisting of:
- (1) kanA, kanB, and kanK;
- (2) kanA, kanB, kanK, and kanF;
- (3) kanA, kanB, kanK, kanF, and kacA;
- (4) kanA, kanB, kanK, kanF, kacA, kanC, and kanD;
- (5) kanA, kanB, kanK, kanF, kacA, kanI, and kacL;
- (6) kanA, kanB, kanK, kanF, kacA, and kanE;
- (7) kanA, kanB, kanK, kanF, kacA, kanE, kanC, and kanD;
- (8) kanA, kanB, kanK, kanF, kacA, kanE, kanI, and kacL;
- (9) kanA, kanB, kanK, kanF, kacA, kanE, kanC, kanD, kanI, and kacL;
- (10) kanA, kanB, kanK, kanF, kacA, kanE, kanC, kanD, btrG, btrH, btrI, btrJ, btrK, btrO, and btrV;
- (11) kanA, kanB, kanK, kanF, kacA, kanE, kanC, kanD, kanI, kacL, btrG, btrH, btrI, btrJ, btrK, btrO, and btrV;
- (12) kanA, kanB, kanK, and nemD;
- (13) kanA, kanB, kanK, nemD, kacA, kanE, kanC, and kanD;
- (14) kanA, kanB, kanK, nemD, kacA, kanE, kanC, kanD, kanI, and kacL;
- (15) kanA, kanB, kanK, nemD, kacA, kanE, kanC, kanD, kanI, kacL, aprD3, and aprD4;
- (16) kanA, kanB, kanK, nemD, kacA, tobM2, kanC, kanD, kanI, kacL, aprD3, and aprD4;
- (17) kanA, kanB, kanK, and tobM1;
- (18) kanA, kanB, kanK, tobM1, kacA, kanE, kanC, and kanD;
- (19) kanA, kanB, kanK, and gtmG;
- and
- (20) kanA, kanB, kanK, gtmG, kacA, kanE, kanC, and kanD.
A compound of formula I or a pharmaceutically acceptable salt thereof:
Dependencies are inferred from the claim text.